Seed · Biotech · Paris, France · Founded 2023 · 20–30 employees
Orakl Oncology is disrupting cancer drug development with an AI-powered platform that creates patient tumor avatars combining real-world data and advanced biology. Founded in 2023 as a spin-off from Europe's leading cancer center Gustave Roussy, the company addresses the 96% clinical trial failure rate in oncology by enabling pharmaceutical companies to predict patient responses and optimize drug development. The startup recently raised €11 million in seed funding led by Singular in December 2024, following a €3 million pre-seed round in 2023, bringing total funding to nearly €15 million. Initially targeting colorectal and pancreatic cancers, areas with significant unmet medical needs, Orakl's platform helps identify therapeutic targets, validate biomarkers, and improve clinical trial success rates.